PRAX insider trading
HealthcarePraxis Precision Medicines, Inc.: insider trade history from SEC Form 4 filings.
About Praxis Precision Medicines, Inc.
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance. The company's platforms include cerebrum, a small molecule platform for CNS small molecule therapies to develop orally available precision therapies; and solidus to discover and develop antisense oligonucleotide. It also develops Ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase 3 clinical trial for the treatment of essential tremor; Vormatrigine, a small molecule targeting the hyperexcitable state of sodium-channels in the brain to treat focal onset epilepsy; Relutrigine for the treatment of developmental and epileptic encephalopathies; PRAX-020 to treat KCNT1; and PRAX-050. In addition, the company develops Elsunersen, a clinical-stage ASO designed to regulate NaV1.2 expression for the treatment of SCN2A-DEE; PRAX-080 that targets PCDH19-related developmental epilepsy; PRAX-090 for targeting SYNGAP1 loss-of-function; and PRAX-100 that targets SCN2A LoF mutations. It has a license agreement with RogCon Inc.; and research collaboration and license agreement with Ionis Pharmaceuticals, Inc. Praxis Precision Medicines, Inc. was incorporated in 2015 and is based in Boston, Massachusetts.
Company website: praxismedicines.com
PRAX insider activity at a glance
FilingIQ tracks 199 insider transactions for PRAX in filings since Oct 20, 2020. The most recent transaction is dated Jul 8, 2026.
Across the full history, 16 open-market purchases
and 41 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on PRAX insider trades is 57.1/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest PRAX Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
13F funds holding PRAX
Frequently asked
- How many insider trades does FilingIQ track for PRAX?
- FilingIQ tracks 199 Form 4 insider transactions for PRAX (Praxis Precision Medicines, Inc.), covering filings from Oct 20, 2020 onwards. 0 of those are dated within the last 90 days.
- Are PRAX insiders net buyers or net sellers?
- Across the full Form 4 history for PRAX, 16 transactions (8%) were open-market purchases and 41 (21%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does PRAX insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ normalises insider identity across reporting variations and scores discretionary open-market purchases and sales on its multi-factor composite model.
- What sector is PRAX in?
- Praxis Precision Medicines, Inc. (PRAX) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $8.89B.
Methodology & sources
Every PRAX insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.